Daniel GoldmanSell
JAZZ · Transaction Jul 12, 2023 · Filed Aug 13, 2023 · $15,001 to $50,000
NASDAQ NMS - GLOBAL MARKET · JAZZ
+0.00% · +$0.0000 · Vol Not reported
Pre-market · updated 04:11:26 ET
Jazz Pharmaceuticals PLC
Pharmaceuticals
$248.36
Veridion Score
BETAHIGH CONF · 6/6 factorsMon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET · JAZZ
MethodologyJAZZ
Jazz Pharmaceuticals PLC
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
66/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is JAZZ moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Jazz Pharmaceuticals PLC
PHARMACEUTICAL PREPARATIONSListed since
2007
Employees
3K
Country
IE
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$248.36
Last session
Day high
$248.36
Last session
Day low
$248.36
Last session
Previous close
$248.36
52W high
$261.62
-5.07% from high
52W low
$117.67
91% of range
Market cap
$15.9B
P/E
16.97×
EPS
$-0.4500
Beta
0.50
Shares out
64.9M
Avg volume
774.5K
VWAP
$248.36
Last session
Price history computed in-house
1W
+0.15%
1M
+0.34%
3M
+3.91%
1Y
+111.06%
YTD
+46.09%
SMA 50 $243.18 · above
SMA 200 $197.74 · above
52W position 91%
JAZZ overview
Related filings and maps
Public disclosures
Congress activity in JAZZ
Official filing ↗
Ro KhannaSell
JAZZ Common Stock · Transaction May 19, 2023 · Filed Jun 12, 2023 · Amount pending receipt enrichment
Ro KhannaBuy
JAZZ Common Stock · Transaction Mar 14, 2023 · Filed Apr 7, 2023 · Amount pending receipt enrichment
JAZZ · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $15,001 to $50,000
Daniel GoldmanSell
JAZZ · Transaction Jan 31, 2023 · Filed Feb 24, 2023 · $1,001 to $15,000
Federal contracts
JAZZ contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for JAZZ in this window.
Lobbying spend
JAZZ lobbying filings, year to date.
Registered lobbying filings matched to Jazz Pharmaceuticals PLC.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for JAZZ in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for JAZZ.
Options
Sovereign unlock shows live options positioning for JAZZ.